Abcam (ABC) Upgraded to “Buy” at Numis Securities

Numis Securities upgraded shares of Abcam (LON:ABC) to a buy rating in a research note published on Friday morning. The firm currently has GBX 1,200 ($16.04) price objective on the stock.

ABC has been the topic of several other research reports. JPMorgan Chase & Co. raised their price target on shares of Abcam from GBX 864 ($11.55) to GBX 946 ($12.65) and gave the company a neutral rating in a report on Monday, September 18th. Peel Hunt raised their price target on shares of Abcam from GBX 750 ($10.03) to GBX 1,020 ($13.64) and gave the company a hold rating in a report on Wednesday, September 20th. Panmure Gordon restated a sell rating on shares of Abcam in a report on Monday, September 11th. Finally, Berenberg Bank restated a buy rating and issued a GBX 1,100 ($14.71) price target on shares of Abcam in a report on Monday, September 11th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of GBX 996 ($13.32).

Abcam (ABC) opened at GBX 1,089 ($14.56) on Friday. Abcam has a 1-year low of GBX 9.73 ($0.13) and a 1-year high of GBX 1,113 ($14.88). The firm has a market cap of $2,230.00 and a PE ratio of 5,185.71.

WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.com-unik.info/2018/01/06/abcam-abc-upgraded-to-buy-at-numis-securities.html.

Abcam Company Profile

Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.

Analyst Recommendations for Abcam (LON:ABC)

What are top analysts saying about Abcam? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Abcam and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit